Develops gene therapies for inherited retinal diseases and eye-drop treatments for other eye disorders, for people with vision conditions.
10-K for FY2025, filed Mar 12, 2026
Viatris reimburses Opus for research and development work; Opus can also receive upfront fees when a license is transferred, milestone payments when milestones are reached, and royalties when partner product sales occur.
8-K, filed Nov 10, 2026 10-K for FY2025, filed Mar 12, 2026Revenue: License and collaborations revenue totaled $1.1 million for the quarter ended September 30, 2026, compared to $3.1 million for the…View ↗
Licenses of intellectual property and research and development services: If the license to the Company’s intellectual property is…View ↗
Milestone payments: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license…View ↗
$14.2M
10-K for FY2025, filed Mar 12, 2026
$14.2M ↗
Viatris is a commercialization partner for phentolamine; it reimburses Opus for development work and handles commercialization for approved indications.
10-K for FY2025, filed Mar 12, 2026 8-K, filed Nov 10, 2026In November 2022, we entered into the Viatris License Agreement for the development and commercialization of all PS indications in the U.S.…View ↗
Revenue: License and collaborations revenue totaled $1.1 million for the quarter ended September 30, 2026, compared to $3.1 million for the…View ↗
No. It lost $49.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$46.5MView ↗
8-K, filed Nov 10, 2026
Received FDA approval of the supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% (RYZUMVI®) for the…View ↗
Growing. Revenue grew 24.1x in 4 years, from $589K in FY2021 to $14.2M in FY2025, about 122% a year.
Shift toward gene therapies
Earlier, the business centered on small-molecule candidates; the latest report centers on gene therapies for inherited retinal diseases while retaining phentolamine eye drops.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 12, 2026Ocuphire is a late clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the…View ↗
Our pipeline is composed of a portfolio of gene therapies being developed as durable, one-time treatments designed to address the…View ↗
Our pipeline features a portfolio of seven adeno-associated virus (“AAV”) based gene therapies that address mutations in genes that cause…View ↗
Our pipeline also includes Phentolamine Ophthalmic Solution 0.75% (PS), a relatively non-selective alpha-1 and alpha-2 adrenergic…View ↗
Competes with MeiraGTX, Octant Bio, Lenz Therapeutics, AbbVie, TenPoint Therapeutics, and Sandoz
10-K for FY2025, filed Mar 12, 2026While we are not currently aware of any direct competitors for our OPGx-LCA5 or OPGx-BEST1 gene therapy program, there are various…View ↗
Loading...